Last reviewed · How we verify
DBPR108; Placebo matching sitagliptin
DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose.
DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose. Used for Placebo control for type 2 diabetes mellitus trials.
At a glance
| Generic name | DBPR108; Placebo matching sitagliptin |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | DPP-4 inhibitor (sitagliptin reference) |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
As a placebo control formulation matched to sitagliptin, DBPR108 itself is inert but designed to be indistinguishable from active sitagliptin in clinical trials. Sitagliptin works by inhibiting DPP-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving these incretin hormones, sitagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion, thereby lowering blood glucose levels in type 2 diabetes patients.
Approved indications
- Placebo control for type 2 diabetes mellitus trials
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: